PMG1015 Dose 7 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 85 | Idiopathic interstitial pneumonia | 1 |
85. Idiopathic interstitial pneumonia
Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05022771 (ClinicalTrials.gov) | October 14, 2021 | 20/8/2021 | A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015 | A Phase 1A, First in Human, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015 in Healthy Volunteers | Idiopathic Pulmonary Fibrosis | Drug: PMG1015 Dose 1;Drug: PMG1015 Dose 2;Drug: PMG1015 Dose 3;Drug: PMG1015 Dose 4;Drug: PMG1015 Dose 5;Drug: PMG1015 Dose 6;Drug: Placebo;Drug: PMG1015 Dose 7 | Pulmongene Ltd. | NULL | Completed | 18 Years | 60 Years | All | 54 | Phase 1 | Australia |